If you haven’t been bombarded with CBD marketing or raves about it from friends, get ready. This extract—which comes from either marijuana or its industrial cousin, hemp—is popping up everywhere. There are CBD capsules, tinctures, and liquids for vaping plus CBD-infused lotions, beauty products, snacks, coffee, and even vaginal suppositories. Already some 1,000 brands of CBD products are available in stores—and online in states that don’t have lenient cannabis laws. This is a tiny fraction of what’s to come: The CBD market is poised to exceed $22 billion by 2022, per the Chicago-based research firm Brightfield Group.
The key is to effectively gauge exactly how much CBD oil it takes to start managing your pain. If you start off right away with a maximum dose of a 600 mg tincture, you will have no idea how much of the product it actually took to treat your condition, and how much you wasted (this is also important because you do not want to exceed dosage and end up developing a tolerance to the active cannabinoids).
Buying online is less reliable still because there’s no regulation or standardization. What you see on the label may not be what you are getting. A 2017 study in JAMA found that of the 84 CBD products researchers bought online, 43 percent had more CBD than indicated, while 26 percent had less, and some had unexpected THC.“There’s a 75 percent chance of getting a product where the CBD is mislabeled,” says Marcu, one of the study’s coauthors.
The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. Please consult your health care professional about potential interactions or other possible complications before using any product.
CBD works by attaching itself to specific receptors of the body’s own endocannabinoid system. The human body is known to produce cannabinoids of its own, which affect the cannabinoid receptors CB1 and CB2. The CB1 receptors are generally found in the brain, and deal with pain, mood and emotions, movement, appetite, among others. THC acts upon the CB1 receptors. Meanwhile, CB2 receptors are more commonly found throughout the immune system, affecting inflammation and thus pain. CBD is thought to act upon these receptors, by influencing the body to produce its own cannabinoids in order to rebalance itself.
Transparency: cbdMD seems to be going through a transition with their third-party testing practices. Until recently, they only released a lab report for the CBD concentrate they use for all their products, but would not show potency testing for individual products. That seems to be changing. Currently, the only lab report on the website is for their concentrate (and it’s over a year old). But if you contact customer service, they’ll send you a lab report for any product.
While it is still classed illegal on a Federal level, individual U.S. states have adopted a more lenient policy towards this plant and some states now allow it for recreational use. The easing up of state laws has also allowed researchers to explore this miraculous plant and only recently has it been found to be an effective treatment for a variety of medical problems due to its CBD oil benefits. From cancer, anorexia, pain and inflammation management it seems like medical marijuana is placing a strong footing within the medical industry.
And we have a long way to go before we fully understand the relationship between CBD and pain regulation. But strong anecdotal evidence, combined with multiple lab tests and even some clinical trials, have established that CBD holds a lot of promise for pain relief. Or in science-speak, CBD “represents a novel class of therapeutic agents for the treatment of chronic pain.”
Green Label hemp oil has the lowest CBD content of our RSHO™ because the cannabinoids in the oil have not been decarboxylated, making Green Label oil higher in CBDa than our other oils, containing a total of 50 mg of CBD per serving. Our popular Blue Label RSHO™ registers in the middle of our pure hemp oil potencies, containing 85 mg of CBD per serving. Finally, our filtered Gold Label RSHO™ tops out with 120 mg of CBD per serving, the highest of any of our products.
There is a strong sedative quality to CBD hemp oil, making it a popular remedy for people with insomnia, sleeplessness, interrupted sleep, post-traumatic stress disorder, restless leg disorder, and other night-time issues. Dr. Scott Shannon, Assistant Clinical Professor of Psychiatry at the University of Colorado School of Medicine, USA, published a report in the Permanete Journal, in which he recommended either inhaling a small amount of CBD oil, applying it to one’s chest, or even putting a few drops on one’s pillow to help get a good night’s sleep.
Vape oil: CBD vape oil is used for vaping CBD. This requires the use of an e-cigarette or vape pen, which can have side effects when chemicals are heated to high temperatures. There are also CBD waxes available that are used for dabbing the cannabis compound. This also requires heating a small amount of the wax and using a dabbing pen. This isn’t recommended for beginners, as it’s usually a higher concentration of CBD.
Most human studies of CBD have been done on people who have seizures, and the FDA recently approved the first CBD-based drug, Epidiolex, for rare forms of epilepsy. Clinical trials for other conditions are promising, but tiny. In one Brazilian study published in 2011 of people with generalized social anxiety disorder, for example, taking a 600-mg dose of CBD (higher than a typical dose from a tincture) lessened discomfort more than a placebo, but only a dozen people were given the pill.
CBD is well tolerated in humans with doses up to 600 mg not resulting in psychotic symptoms (15). In the few small placebo-controlled studies performed, no significant CNS effects were noted. Oral CBD undergoes extensive first-pass metabolism via CYP3A4, with a bioavailability of 6%. Following single doses in humans, the half-life of CBD when taken orally is about 1 to 2 days.1 In vitro studies have shown that CBD is a potent inhibitor of multiple CYP isozymes, including CYP 2C and CYP3A (16, 17). Whether these in vitro observations are relevant at plasma concentrations likely to be seen in patients is unclear. In addition, given its metabolism via CYP3A4, clinical trials of CBD in patients receiving enzyme-inducing AEDs, such as carbamazepine or phenytoin, will require detailed pharmacokinetic studies.
When administered alone, CBD is an effective anticonvulsant in maximal electrical shock (MES), magnesium-free, 4-aminopyridine, and audiogenic models (7, 8). Co-administration with AEDs leads to various effects; anticonvulsant effects of CBD are enhanced with phenytoin or phenobarbital but decreased with chlordiazepoxide, clonazepam, trimethadione, and ethosuximide. In a recent study using an acute pilocarpine model, although CBD administration reduced the number of animals displaying seizure activity, CBD did not appear to have any significant effect on the number of seizures per animal (7).